NCT02582073 is a Phase 2 clinical trial of Grass MATA MPL (0.5ml) 5100SU in Seasonal Allergic Rhinitis, sponsored by Allergy Therapeutics.

Who is sponsoring NCT02582073?

NCT02582073 is sponsored by Allergy Therapeutics.

What drugs are being tested in NCT02582073?

Interventions in NCT02582073: Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU.

What condition does NCT02582073 study?

NCT02582073 studies Seasonal Allergic Rhinitis.

Is NCT02582073 still recruiting?

NCT02582073 is currently completed. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT02582073

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Completed Phase 2 Last updated 29 January 2021

What this trial tests

Phase 2 trial testing Placebo (0.5ml) in Seasonal Allergic Rhinitis in 265 participants. Completed in 28 April 2017.

Timeline

7 November 2015

Primary endpoint
5 May 2016

28 April 2017

Quick facts

Lead sponsor	Allergy Therapeutics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	265
Start date	7 November 2015
Primary completion	5 May 2016
Estimated completion	28 April 2017
Sites	1 location across United States

Drugs / interventions tested

Placebo (0.5ml)
Placebo (1.0ml) — full drug profile →
Grass MATA MPL (0.5ml) 5100SU — full drug profile →
Grass MATA MPL (1.0ml) 10200SU — full drug profile →
Grass MATA MPL (1.0ml) 18200SU — full drug profile →
Grass MATA (0.5ml) 5100SU — full drug profile →

Conditions studied

Seasonal Allergic Rhinitis — all drugs for Seasonal Allergic Rhinitis →

Sponsor

Allergy Therapeutics — full company profile →

Who can join

Adults 18 to 50, any sex, with Seasonal Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. The current therapeutic dose regimen for Grass MATA MPL is a course of four injections of 300, 800, 2000 and 2000 SU (Standardized Units), administered at weekly intervals (cumulative dose 5100 SU). Two new cumulative doses of the Grass MATA MPL 10200 SU and 18200 SU are being developed to compare with the current dose. The study is designed to explore the benefit/risk of increasing the cumulative allergen dose of the Grass MATA MPL immunotherapy comparing these doses with the current dose of Grass MATA MPL, Grass MATA (without MPL) and placebo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent clinical trends in Toll-like receptor targeting therapeutics.
Anwar MA, Shah M, Kim J, Choi S. · · 2019 · cited 209× · PMID 30450666 · DOI 10.1002/med.21553

Verify or expand the search:

Other recruiting trials for Seasonal Allergic Rhinitis

Currently open trials in the same condition.

NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
NCT06846385 — Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic · Phase 2, PHASE3 · recruiting
NCT07291284 — Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis · Phase 3 · active not recruiting
NCT06300203 — Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis · Phase 2 · recruiting
NCT04815668 — Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis · NA · recruiting

Other Allergy Therapeutics trials

Trials by the same sponsor.

NCT07412990 — GRASS (Grass MATA MPL Real-world Assessment Study) · recruiting
NCT05540717 — Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass · Phase 3 · completed
NCT05455749 — Effect of holoBLG on Cat Allergic Patients · NA · completed
NCT04687059 — An Exploratory Study of PQ Grass 27600 SU · Phase 2, PHASE3 · completed
NCT04389034 — Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (Ig · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02582073 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergy Therapeutics
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02582073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing